150 related articles for article (PubMed ID: 26444918)
1. EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?
Busato Júnior WF; Almeida GL; Ribas CA; Ribas Filho JM; De Cobelli O
Clin Genitourin Cancer; 2016 Apr; 14(2):176-82. PubMed ID: 26444918
[TBL] [Abstract][Full Text] [Related]
2. External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1.
Almeida GL; Busato WF; Ribas CM; Ribas JM; De Cobelli O
Int Braz J Urol; 2016; 42(5):932-941. PubMed ID: 27509372
[TBL] [Abstract][Full Text] [Related]
3. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
[TBL] [Abstract][Full Text] [Related]
4. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
[TBL] [Abstract][Full Text] [Related]
5. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
7. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
[TBL] [Abstract][Full Text] [Related]
8. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
[TBL] [Abstract][Full Text] [Related]
11. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
Ather MH; Zaidi M
Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
[TBL] [Abstract][Full Text] [Related]
12. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
[No Abstract] [Full Text] [Related]
13. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
Zhang G; Steinbach D; Grimm MO; Horstmann M
World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
Xylinas E; Kent M; Kluth L; Pycha A; Comploj E; Svatek RS; Lotan Y; Trinh QD; Karakiewicz PI; Holmang S; Scherr DS; Zerbib M; Vickers AJ; Shariat SF
Br J Cancer; 2013 Sep; 109(6):1460-6. PubMed ID: 23982601
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of TaG1 non-muscle-invasive bladder cancer.
Olivier Bosset P; Neuzillet Y; Paoletti X; Molinie V; Botto H; Lebret T
Urol Oncol; 2015 Jan; 33(1):20.e1-20.e7. PubMed ID: 25282704
[TBL] [Abstract][Full Text] [Related]
17. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
18. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models.
Xu T; Zhu Z; Zhang X; Wang X; Zhong S; Zhang M; Shen Z
Urology; 2013 Aug; 82(2):387-93. PubMed ID: 23759377
[TBL] [Abstract][Full Text] [Related]
19. Risk-based Management of Non-muscle Invasive Bladder Cancer: Experience from Tribhuvan University Teaching Hospital.
Luitel BR; Chalise PR; Nathani S; Gupta DK; Subedi P; Chapagain S; Sharma UK; Gyawali PR; Shrestha GK; Joshi BR
Kathmandu Univ Med J (KUMJ); 2016 Oct.-Dec.; 14(56):352-356. PubMed ID: 29371493
[TBL] [Abstract][Full Text] [Related]
20. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
